Gyre Therapeutics Balance Sheet
NASDAQ: GYREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Gyre Therapeutics financial position
At the end of fiscal 2025, Gyre Therapeutics reported total assets of $219.8 million, up 75.2% from a year earlier against total liabilities of $31.4 million. Shareholders' equity stood at $62.5 million, or 28.4% of assets. The company held $49.2 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 6.28, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Gyre Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 49.19M | 11.81M | 33.51M | 25.18M | 44.35M | 30.36M | 15.37M | 31.21M | 14.47M | 10.26M |
| Short-Term Investments | 15.36M | 14.86M | — | 0 | 2.50M | 48.99M | 61.50M | 88.91M | 17.97M | 6.80M |
| Receivables | 31.08M | 19.59M | 15.16M | 17.14M | 1.82M | 3.31M | 15.00M | — | — | — |
| Inventory | 10.17M | 6.34M | 4.28M | 6.12M | — | — | — | — | — | — |
| Total Current Assets | 149.36M | 64.79M | 57.22M | 49.65M | 51.48M | 89.51M | 96.07M | 123.99M | 39.11M | 37.52M |
| Property, Plant & Equipment | 27.55M | 23.88M | 23.29M | 17.71M | 970.00K | 433.00K | 304.00K | 386.00K | 276.00K | 444.00K |
| Intangible Assets | 4.73M | 273.00K | 273.00K | 297.00K | — | — | — | — | — | — |
| Long-Term Investments | 1.59M | 1.60M | — | — | — | 2.54M | — | — | — | — |
| Total Assets | 219.76M | 125.41M | 116.54M | 84.75M | 55.66M | 94.85M | 98.55M | 124.92M | 39.51M | 38.09M |
| Accounts Payable | 1.33M | 108.00K | 355.00K | 122.00K | 6.42M | 5.93M | 4.28M | 1.25M | 747.00K | 837.00K |
| Total Current Liabilities | 23.78M | 19.52M | 20.05M | 12.24M | 14.16M | 17.80M | 28.90M | 4.80M | 8.74M | 21.96M |
| Total Liabilities | 31.40M | 27.00M | 38.06M | 12.54M | 14.57M | 18.78M | 30.22M | 4.97M | 8.74M | 22.02M |
| Shareholders' Equity | 62.50M | 63.32M | -15.83M | 42.52M | 41.09M | 76.07M | 68.34M | 119.94M | 30.77M | 16.07M |
| Retained Earnings | -112.60M | -73.45M | -85.54M | 7.39M | -402.69M | -314.76M | -258.52M | -203.34M | -173.49M | -147.98M |
| Net Cash (Debt) | 64.55M | 26.67M | 33.51M | 25.18M | 46.85M | 79.35M | 76.86M | 120.13M | 32.44M | 17.06M |
| Shares Outstanding | 91.31M | 86.31M | 76.60M | 63.59M | 31.41M | 22.10M | 12.04M | 11.95M | 6.08M | 801.76K |
This table shows 10 annual periods of Gyre Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow GYRE's reporting calendar. What is a balance sheet?